Literature DB >> 16219641

Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features.

A Volpe1, D Biasi, P Caramaschi, W Mantovani, L M Bambara, S Canestrini, M Ferrari, G Poli, M Degan, A Carletto, S Pieropan, P Minuz.   

Abstract

OBJECTIVE: Oxidative stress may be one of the important complex pathogenetic mechanisms that lead to damage in scleroderma; free radicals may provoke endothelial injury, fibroblast proliferation and fragmentation of autoantigens favouring induction of autoantibodies. The present study investigates the oxidant status in scleroderma patients by measuring the urinary concentration of 8-isoprostaglandin-F2alpha, an F2-isoprostane, and a product of free radical-mediated peroxidation of arachidonic acid.
METHODS: Forty-three scleroderma patients (42 women and 1 man, mean age 54.1 yr, mean disease duration 9.0 yr) underwent clinical evaluation and instrumental investigations in order to assess skin, vascular, lung and heart involvement. Von Willebrand factor was evaluated as marker of vascular dysfunction in 36 out of the 43 cases. The urinary level of 8-isoprostaglandin-F2alpha was measured in all scleroderma patients and in the 43 age- and sex-matched healthy controls.
RESULTS: Urinary levels of 8-isoprostaglandin-F2alpha were higher in scleroderma patients than in the healthy control group (341.7 vs 147.6 pg/mg creatinine; P < 0.001). Values of 8-isoprostaglandin-F2alpha were strongly correlated with the nailfold videocapillaroscopy pattern and lung involvement (P = 0.002 and 0.003, respectively), showing increasing levels with the progression of pulmonary severity. Correlation between 8-isoprostaglandin-F2alpha level and von Willebrand factor narrowly failed to reach statistical significance (P = 0.05). There was no correlation between 8-isoprostaglandin-F2alpha concentration and disease activity, vascular, skin and heart involvement, disease pattern or autoantibody profile.
CONCLUSIONS: Our study further supports the role of oxidant stress in the pathogenesis of scleroderma, showing a strong correlation between a marker of free radical damage with both the severity of lung involvement and the videocapillaroscopic patterns.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219641     DOI: 10.1093/rheumatology/kei151

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  12 in total

1.  Antiphospholipid antibodies in systemic sclerosis: a double oxidative hit?

Authors:  Paul R J Ames
Journal:  Clin Rheumatol       Date:  2009-06-10       Impact factor: 2.980

Review 2.  Application of biomarkers to clinical trials in systemic sclerosis.

Authors:  Robert Lafyatis
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

3.  Genistein protects dermal fibrosis in bleomycin-induced experimental scleroderma.

Authors:  Süleyman Serdar Koca; Adile Ferda Dağlı; Servet Yolbaş; Nevzat Gözel; Ahmet Işık
Journal:  Eur J Rheumatol       Date:  2015-05-20

Review 4.  Microvascular damage in systemic sclerosis: detection and monitoring with biomarkers.

Authors:  Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

5.  Organ involvement in Argentinian systemic sclerosis patients with "late" pattern as compared to patients with "early/active" pattern by nailfold capillaroscopy.

Authors:  Lucila Marino Claverie; Elizabeth Knobel; Lorena Takashima; Lorena Techera; Marina Oliver; Paula Gonzalez; Félix E Romanini; María L Fonseca; Marta N Mamani
Journal:  Clin Rheumatol       Date:  2013-02-16       Impact factor: 2.980

6.  Levels of F2 isoprostane in Behcet's disease: Correlation with cardiometabolic risk factors.

Authors:  Gul Sagun; Aytekin Oguz; Banu Mesci; Banu Isbilen; Mukaddes Kavala; Havva Keskin; Mumtaz Takir; Sibel Zehra Aydin
Journal:  Redox Rep       Date:  2015-04-13       Impact factor: 4.412

Review 7.  Role of cellular senescence and NOX4-mediated oxidative stress in systemic sclerosis pathogenesis.

Authors:  Sonsoles Piera-Velazquez; Sergio A Jimenez
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

Review 8.  Biomarkers of scleroderma lung disease: recent progress.

Authors:  Faye N Hant; Richard M Silver
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

9.  A Pilot Study of Dimethyl Fumarate in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis.

Authors:  Kristi Kong; Diane Koontz; Christina Morse; Eileen Roth; Robyn T Domsic; Marc A Simon; Eric Stratton; Connor Buchholz; Kimberly Tobin-Finch; Robert Simms; M Patricia George; Paul M Hassoun; Harrison Farber; Robert Lafyatis
Journal:  J Scleroderma Relat Disord       Date:  2021-05-28

10.  Iloprost infusion does not reduce oxidative stress in systemic sclerosis.

Authors:  Alessandro Volpe; Domenico Biasi; Paola Caramaschi; Lisa Maria Bambara; Antonio Carletto; Maurizio Degan; Pietro Minuz
Journal:  Rheumatol Int       Date:  2007-08-18       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.